Matches in Wikidata for { <http://www.wikidata.org/entity/Q96165527> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- Q96165527 description "article scientifique publié en 2020" @default.
- Q96165527 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96165527 description "scientific article published on 05 June 2020" @default.
- Q96165527 description "wetenschappelijk artikel" @default.
- Q96165527 description "наукова стаття, опублікована 5 червня 2020" @default.
- Q96165527 name "Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models" @default.
- Q96165527 name "Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models" @default.
- Q96165527 type Item @default.
- Q96165527 label "Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models" @default.
- Q96165527 label "Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models" @default.
- Q96165527 prefLabel "Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models" @default.
- Q96165527 prefLabel "Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models" @default.
- Q96165527 P1433 Q96165527-8E26383B-FBBD-44B2-95ED-A843E957A116 @default.
- Q96165527 P1476 Q96165527-2E533160-D119-4F23-92A9-BA4D27802DDB @default.
- Q96165527 P2093 Q96165527-023B9A41-4167-4646-8FDD-F240339CFC57 @default.
- Q96165527 P2093 Q96165527-03B29602-C604-44DF-BF93-833A10CE8700 @default.
- Q96165527 P2093 Q96165527-04C8CC9C-535D-4170-AA3C-5E394F1E0ABA @default.
- Q96165527 P2093 Q96165527-0B5FB4FC-E3D8-4AAA-82D3-924DE2157C3D @default.
- Q96165527 P2093 Q96165527-0E9F1204-A0E8-4142-9E47-CE72FAA5579C @default.
- Q96165527 P2093 Q96165527-17FBF18F-05A3-4314-906B-9579F3ADC345 @default.
- Q96165527 P2093 Q96165527-1C90275D-343C-4223-A576-DD17417A823B @default.
- Q96165527 P2093 Q96165527-2327D651-5407-4850-898D-F120C2F19894 @default.
- Q96165527 P2093 Q96165527-26CF3E03-A616-4D5F-A6F4-1542CE653EF1 @default.
- Q96165527 P2093 Q96165527-41197704-49D5-4E1F-8B57-94E4012C35EE @default.
- Q96165527 P2093 Q96165527-42F41CFC-8784-4EC5-AC35-8233B5A9FBAC @default.
- Q96165527 P2093 Q96165527-6922FE8B-C057-44B0-BE4B-AC4A31716C37 @default.
- Q96165527 P2093 Q96165527-7B9E1D6E-8536-43FE-81CC-AE25BAA9C1FD @default.
- Q96165527 P2093 Q96165527-7C85537A-56B2-404D-BAE5-A049BCFCA1E5 @default.
- Q96165527 P2093 Q96165527-84DC6866-910F-4119-808C-523EC7C52E25 @default.
- Q96165527 P2093 Q96165527-8956AD02-8A1A-4D96-9111-BFB204209E14 @default.
- Q96165527 P2093 Q96165527-8FE7C9E6-289A-49CC-B9C9-00B784BFFFA6 @default.
- Q96165527 P2093 Q96165527-982C7BF3-ED18-4B33-9453-25EAC74F052A @default.
- Q96165527 P2093 Q96165527-9BE482E8-D300-40AF-A912-0B79C2AE8918 @default.
- Q96165527 P2093 Q96165527-BF1351AB-6E17-4111-BE0F-9559E97F6507 @default.
- Q96165527 P2093 Q96165527-EFEE842D-05AD-4310-8A58-741ACFAB28DC @default.
- Q96165527 P2093 Q96165527-FA17F76A-ED75-47A3-9D16-577756F27F1E @default.
- Q96165527 P31 Q96165527-2B680678-C2DB-4879-86C7-A293B21A6181 @default.
- Q96165527 P356 Q96165527-F65A2B28-8BDB-4B7D-86CF-A727D3641B68 @default.
- Q96165527 P50 Q96165527-6F174C18-4F13-4EB1-83DE-CAB1249ECBA4 @default.
- Q96165527 P577 Q96165527-11B10ACB-0C04-43BB-BDC8-32FDEA77D2E4 @default.
- Q96165527 P698 Q96165527-726E9254-CAA8-48E0-A6D1-D135FD2E4B60 @default.
- Q96165527 P921 Q96165527-6BCF8220-34CB-4EC8-9061-03BC715488CD @default.
- Q96165527 P356 ACS.JMEDCHEM.0C00369 @default.
- Q96165527 P698 32502336 @default.
- Q96165527 P1433 Q900316 @default.
- Q96165527 P1476 "Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models" @default.
- Q96165527 P2093 "Antje Margret Wengner" @default.
- Q96165527 P2093 "Benjamin Bader" @default.
- Q96165527 P2093 "Christoph Schatz" @default.
- Q96165527 P2093 "Dieter Moosmayer" @default.
- Q96165527 P2093 "Dominik Mumberg" @default.
- Q96165527 P2093 "Florian Bartels" @default.
- Q96165527 P2093 "Franz von Nussbaum" @default.
- Q96165527 P2093 "Gerhard Siemeister" @default.
- Q96165527 P2093 "Gesa Deeg" @default.
- Q96165527 P2093 "Hans Briem" @default.
- Q96165527 P2093 "Joanna Grudzinska-Goebel" @default.
- Q96165527 P2093 "Julien Lefranc" @default.
- Q96165527 P2093 "Karsten Denner" @default.
- Q96165527 P2093 "Knut Eis" @default.
- Q96165527 P2093 "Marcus Koppitz" @default.
- Q96165527 P2093 "Martina Schaefer" @default.
- Q96165527 P2093 "Philip Lienau" @default.
- Q96165527 P2093 "Simon J Holton" @default.
- Q96165527 P2093 "Ulf Boemer" @default.
- Q96165527 P2093 "Ulrich Luecking" @default.
- Q96165527 P2093 "Uwe Eberspächer" @default.
- Q96165527 P2093 "Wilhelm Bone" @default.
- Q96165527 P31 Q13442814 @default.
- Q96165527 P356 "10.1021/ACS.JMEDCHEM.0C00369" @default.
- Q96165527 P50 Q60619092 @default.
- Q96165527 P577 "2020-06-05T00:00:00Z" @default.
- Q96165527 P698 "32502336" @default.
- Q96165527 P921 Q323936 @default.